КЕРАМИЧЕСКИЕ НАНОПОКРЫТИЯ НА СФЕРИЧЕСКИХ ПОРОШКАХ: АЛЬТЕРНАТИВНЫЙ СПОСОБ ПОЛУЧЕНИЯ ПОРИСТЫХ ПОРОШКОВЫХ МАТЕРИАЛОВ

A technology has been developed to obtain porous powder materials on the basis of spherecal powder particles of 12Х18Н10T сorrosion-resistant steel by technological coating deposition on them –condensate from layered and composite Si and (Si + C) or Si and (Mo + Si) nano-layers. Their deformation at points of spherical particles contact creates press forming conditions with sufficient strength rate at pressure below yield point of steel powder (below 200 MPa). The subsequent sintering occurring  with an exothermic reaction in the coating ensures particle sintering in their local heating within 1100–1200 °С temperature range.Разработана технология получения пористых порошковых материалов на основе сферических частиц порошка коррозионностойкой стали 12Х18Н10Т путем нанесения на них технологических покрытий – конденсата из слоистых и композиционных нанослоев Si и (Si + С) или Si и (Мо + Si), деформация которых в точках контакта сферических частиц при давлении ниже предела текучести порошка стали (ниже 200 МПа) создает условия формования прессовки с достаточным уровнем прочности, а последующее реакционное спекание, протекающее с экзотермической реакцией в покрытии, обеспечивает спекание частиц при локальном их разогреве в диапазоне температур 1100–1200 оС.

Comparative analysis of using natural and radiogenic lead as heat-transfer agent in fast reactors

Fast reactors with lead coolant have several advantages over analogues. Performance can be further improved by replacement of natural composition lead with radiogenic one. Thus, two main issues need to be addressed: induced radioactivity in coolant and efficient neutron multiplication factor in the core will be changed and need to be estimated. To address these issues analysis of the scheme of the nuclear transformations in the lead heat-transfer agent in the process of radiation was carried out. Induced radioactivity of radiogenic and natural lead has been studied. It is shown that replacement of lead affects multiplication factor in a certain way. Application of radiogenic lead can significantly affect reactor operation

CERAMIC NANO-COATINGS ON SPHERICAL POWDERS: ALTERNATIVE METHOD FOR OBTAINING POROUS POWDER MATERIALS

A technology has been developed to obtain porous powder materials on the basis of spherecal powder particles of 12Х18Н10T сorrosion-resistant steel by technological coating deposition on them –condensate from layered and composite Si and (Si + C) or Si and (Mo + Si) nano-layers. Their deformation at points of spherical particles contact creates press forming conditions with sufficient strength rate at pressure below yield point of steel powder (below 200 MPa). The subsequent sintering occurring  with an exothermic reaction in the coating ensures particle sintering in their local heating within 1100–1200 °С temperature range

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)